VTGN
Vistagen Therapeutics, Inc.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $3.41 | $0.60 | -82% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $3.28 | $0.60 | -82% |
| Millennium Management re-entered | Q4 2024(8Q snapshot) | 6Q | $2.73 | $0.60 | -78% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 2× in & out | Q4 2025 | Q1 2026 | → $0.53 | -86% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Vistagen Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 19, 2026 — the most recent Form 4 on file — not from today.
- Form 40002132062-26-000004May 19, 2026
- Form 40001794362-26-000002Apr 9, 2026
- Form 40001412071-26-000004Apr 9, 2026
- Form 40001998663-26-000006Apr 9, 2026
- Form 40002069951-26-000004Apr 9, 2026
- Form 40001924908-26-000005Apr 9, 2026
- Form 40001998663-26-000002Jan 5, 2026
- Form 40001794362-25-000005Dec 4, 2025
- Form 40001531178-25-000007Nov 4, 2025
- Form 40001411685-25-000078Sep 11, 2025
- Form 40001411685-25-000077Sep 11, 2025
- Form 40001411685-25-000076Sep 11, 2025
- Form 40001411685-25-000075Sep 11, 2025
- Form 40001411685-25-000074Sep 11, 2025
- Form 40001415889-25-018759Jul 1, 2025
Fundamentals
XBRL · Vistagen Therapeutics, Inc.Annual figures sourced directly from Vistagen Therapeutics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Vistagen Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 9, 2026
- 8-KMaterial eventMay 19, 2026
- 8-KMaterial eventMay 12, 2026
- 8-KMaterial eventMay 8, 2026
- 8-KMaterial eventApr 28, 2026
- 8-KMaterial eventApr 13, 2026
- 8-KMaterial eventApr 2, 2026
- 8-KMaterial eventMar 18, 2026
- 8-KMaterial eventMar 16, 2026
- 8-KMaterial eventMar 11, 2026
- 8-KMaterial eventFeb 20, 2026
- 10-QQuarterly reportFeb 12, 2026
- 8-KMaterial eventFeb 12, 2026
- 8-KMaterial eventFeb 6, 2026
- 8-KMaterial eventJan 9, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q4 2025 | Q1 2026 | $3.80 | $0.53 | -86% |
| Millennium Management | Q4 2025 | open | $3.80 | $0.60 | -84% |
| Millennium Management | Q4 2024 | Q2 2025 | $2.73 | $2.30 | -16% |
| Citadel Advisors | Q3 2024 | Q1 2025 | $3.28 | $2.97 | -9% |
| Two Sigma Investments | Q3 2024 | open | $3.28 | $0.60 | -82% |
| Renaissance Technologies | Q3 2024 | open | $3.41 | $0.60 | -82% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.